Aung Naing

433 total citations
35 papers, 278 citations indexed

About

Aung Naing is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Aung Naing has authored 35 papers receiving a total of 278 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 9 papers in Immunology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Aung Naing's work include Cancer Immunotherapy and Biomarkers (13 papers), Colorectal Cancer Treatments and Studies (7 papers) and CAR-T cell therapy research (6 papers). Aung Naing is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Colorectal Cancer Treatments and Studies (7 papers) and CAR-T cell therapy research (6 papers). Aung Naing collaborates with scholars based in United States, Spain and United Kingdom. Aung Naing's co-authors include David S. Hong, Gerald S. Falchook, Jennifer J. Wheler, Razelle Kurzrock, Patricia LoRusso, James P. O’Brien, Mary Jo Pilat, Jade S. Schiffman, Sarina A. Piha‐Paul and John D. Powderly and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Aung Naing

33 papers receiving 274 citations

Peers

Countries citing papers authored by Aung Naing

Since Specialization

Citations

This map shows the geographic impact of Aung Naing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aung Naing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aung Naing more than expected).

Fields of papers citing papers by Aung Naing

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aung Naing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aung Naing. The network helps show where Aung Naing may publish in the future.

Co-authorship network of co-authors of Aung Naing

This figure shows the co-authorship network connecting the top 25 collaborators of Aung Naing. A scholar is included among the top collaborators of Aung Naing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aung Naing. Aung Naing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	IGF-1R inhibitors in cancer: A review of available evidence and future outlook 2025 ·Critical Reviews in Oncology/Hematology ·Deniz Can Güven, Jibran Ahmed, Bettzy Stephen, Aung Naing	1
2	A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer 2025 ·Gynecologic Oncology ·Jibran Ahmed, Bettzy Stephen, Muhammad Rizwan Khawaja, (unknown), (unknown), (unknown), Maria Gabriela Raso, Daniel D. Karp, Sarina A. Piha‐Paul, Anil K. Sood, Chaan S. Ng, Amber M. Johnson, Pamela T. Soliman, Funda Meric‐Bernstam, Karen H. Lu, Aung Naing	4
3	A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors. 2024 ·Journal of Clinical Oncology ·Mohamed A. Gouda, (unknown), Aung Naing, Ecaterina E. Dumbrava, David S. Hong, Ying Yuan, Peiying Yang, Alan L. Myers, Yulong Liang, Jing Ping, Daniel D. Karp, Apostolia M. Tsimberidou, Jordi Rodón, Timothy A. Yap, Sarina A. Piha‐Paul, Funda Meric‐Bernstam, Siqing Fu	1
4	A phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat gastrointestinal tumors. 2024 ·Journal of Clinical Oncology ·Richard D. Kim, Hirva Mamdani, Minal Barve, Melissa L. Johnson, Julie A. Murphy, (unknown), Sara Ferrando‐Martínez, Byung Ha Lee, Se Hwan Yang, Marya Chaney, Aung Naing	1
5	A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors 2024 ·ESMO Open ·Mohamed A. Gouda, (unknown), Aung Naing, Ecaterina E. Dumbrava, David S. Hong, Ying Yuan, Pan‐Chyr Yang, Andrea P. Myers, Yan Liang, Jie Peng, (unknown), Apostolia M. Tsimberidou, Jordi Rodón, Timothy A. Yap, Sarina A. Piha‐Paul, Funda Meric‐Bernstam, Siqing Fu	2
6	Phase I dose-escalation and cohort expansion study of the anti-BTLA antibody, tifcemalimab, in combination with toripalimab (anti-PD-1) in heavily pretreated patients (pts) with advanced malignancies. 2024 ·Journal of Clinical Oncology ·T. Vincent, Mohammed Milhem, Manuel Hidalgo, Anthony F. Shields, Jennifer Segar, Maya Khalil, Andrew A. Davis, Claire F. Verschraegen, Deborah J. Wong, (unknown), Xin Gao, John D. Powderly, Yixing Jiang, Rahul Aggarwal, Farrukh T. Awan, Meredith McKean, Warren Chow, Sheng Yao, Patricia Keegan, Aung Naing	3
7	1074TiP A phase I/II, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors 2023 ·Annals of Oncology ·Martin Gutierrez, Elena Garralda, Emiliano Calvo, Martien van Dongen, Ferry A.L.M. Eskens, Malcolm Finlay, (unknown), Chenjing Zhu, Meng Wu, (unknown), Giovanni Abbadessa, Raymond P. Perez, Onur Yıldırım, Aung Naing	2
8	652 NT-I7 (efineptakin alfa), a long-acting IL-7, in combination with pembrolizumab improves T cell fitness in heavily pretreated subjects with gastrointestinal tumors 2023 ·SHILAP Revista de lepidopterología ·Aung Naing, Hirva Mamdani, Minal Barve, Meredith Pelster, Cara Haymaker, (unknown), (unknown), Samuel Darko, Julie A. Murphy, (unknown), (unknown), Sara Ferrando‐Martínez, Byung Ha Lee, Se Hwan Yang, Siyoung Lee, Marya Chaney, Richard D. Kim	1
9	Abstract 6181: Dynamic changes in monocyte and reticulocyte counts predict mechanism-based anemia development and recovery during ATR inhibitor treatment in phase I/II trials 2023 ·Cancer Research ·Natalie Y.L. Ngoi, Heather Lin, Ecaterina E. Dumbrava, Siqing Fu, Daniel D. Karp, Aung Naing, Shubham Pant, Sarina A. Piha‐Paul, Jordi Rodón, Vivek Subbiah, Apostolia M. Tsimberidou, (unknown), (unknown), David S. Hong, Funda Meric‐Bernstam, Ying Yuan, Timothy A. Yap	2
10	Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience 2022 ·Journal of Hematology ·Blessie Elizabeth Nelson, (unknown), Bettzy Stephen, (unknown), (unknown), Jing Gong, David S. Hong, Siqing Fu, Timothy A. Yap, Mariela Blum Murphy, Sarina A. Piha‐Paul, Naval Daver, Cristhiam M. Rojas‐Hernandez, Aung Naing	5
11	Effect of immunotherapy and time-of-day infusion chronomodulation on survival in advanced cancers. 2022 ·Journal of Clinical Oncology ·Blessie Elizabeth Nelson, Clark R. Andersen, Ying Yuan, David S. Hong, Aung Naing, Daniel D. Karp, Timothy A. Yap, Jordi Rodón, (unknown), Apostolia M. Tsimberidou, Ecaterina E. Dumbrava, Siqing Fu, Sarina A. Piha‐Paul, Shubham Pant, George R. Blumenschein, Mehmet Altan, Hussein A. Tawbi, Nizar M. Tannir, Funda Meric‐Bernstam, Vivek Subbiah	5
12	747 A phase 1 trial of IO-202, an antagonist antibody targeting myeloid checkpoint LILRB4 (ILT3), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors 2022 ·Regular and Young Investigator Award Abstracts ·Aung Naing, (unknown), Meredith Pelster, Alexander I. Spira, Reva Schneider, Paul Woodard, (unknown), Elizabeth A. Wieland, (unknown), Kyu Hong, Tao Huang, Xuebin Liao, Hong Xiang, Heinz‐Josef Lenz, Wen Lin	4
13	Phase Ia dose-escalation study of the anti-BTLA antibody icatolimab as a monotherapy in patients with advanced solid tumor. 2022 ·Journal of Clinical Oncology ·Russell J. Schilder, John D. Powderly, Haeseong Park, Mehmet Asım Bilen, Meredith McKean, Rena J. May, Hui Feng, Sheng Yao, Patricia Keegan, Aung Naing	15
14	Efficacy and safety of NT-I7, long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: Results from the phase 2a study. 2022 ·Journal of Clinical Oncology ·Aung Naing, Hirva Mamdani, Minal Barve, Melissa L. Johnson, Daniel Morgensztern, Anthony J. Olszanski, Robert A. Wolff, Shubham Pant, Marya Chaney, (unknown), Jean Fan, Richard D. Kim, Scott Kopetz	4
15	A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies 2021 ·OncoTargets and Therapy ·Sarina A. Piha‐Paul, Ecaterina E. Dumbrava, Binoj C. Nair, (unknown), Xu Li, (unknown), Vivek Subbiah, Nizar M. Tannir, Siqing Fu, Aung Naing, Filip Jankú, Daniel D. Karp, Shreyaskumar Patel, Najat C. Daw, David S. Hong, Funda Meric‐Bernstam, Ralph Zinner	2
16	Abstract 3418: A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The salivary gland tumor cohort 2020 ·Cancer Research ·Young Kwang Chae, Megan Othus, Sandip Pravin Patel, James Ohr, Francis P. Worden, Jennifer M. Suga, Aung Naing, Sarah E. Fenton, Hyunseok Kang, (unknown), Christine M. McLeod, Francis J. Giles, Helen X. Chen, Elad Sharon, Edward Mayerson, Melissa Plets, Christopher W. Ryan, Charles D. Blanke, Razelle Kurzrock	5
17	Sofosbuvir-based therapy in patients with chronic hepatitis C virus infection and malignancies: A prospective study of 143 patients. 2017 ·Journal of Clinical Oncology ·Harrys A. Torres, Minas P. Economides, Andreas Kyvernitakis, Parag Mahale, Jeff Hosry, Aung Naing, Francesco Turturro, Ahmed O. Kaseb, Issam Raad, Bruno Granwehr	4
18	Clinical next-generation sequencing to identify actionable alterations in a phase I program. 2014 ·Journal of Clinical Oncology ·Genevieve M. Boland, Sarina A. Piha‐Paul, Vivek Subbiah, Lauren Brusco, Shelley M. Herbrich, Keith Baggerly, Mark J. Routbort, Keyur Patel, Rajyalakshmi Luthra, Aung Naing, Siqing Fu, Gerald S. Falchook, David S. Hong, Jennifer J. Wheler, Filip Jankú, Kenna Shaw, Kenneth Aldape, John Mendelsohn, Gordon B. Mills, Funda Meric‐Bernstam	1
19	A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors 2013 ·Investigational New Drugs ·David S. Hong, Razelle Kurzrock, Aung Naing, Jennifer J. Wheler, Gerald S. Falchook, Jade S. Schiffman, (unknown), Mary Jo Pilat, James P. O’Brien, Patricia LoRusso	163
20	A phase I study of bevacizumab in combination with sunitinib, sorafenib, and erlotinib plus cetuximab, and trastuzumab plus lapatinib. 2010 ·Journal of Clinical Oncology ·Gerald S. Falchook, Jennifer J. Wheler, Aung Naing, David S. Hong, Stacy L. Moulder, Sarina A. Piha‐Paul, C.S. Ng, Erica L. Jackson, Razelle Kurzrock	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact